CD388 not checked

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) · MK-1406

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
4 active
7 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“MK-1406 liquid for injection administered subcutaneously (SC)”In the company’s words, NCT07159763 on ClinicalTrials.gov
Tested for
Influenza
Main trialPhase 3
“Approximately one billion cases of seasonal influenza occur annually. Of these, 3 to 5 million illnesses are severe and responsible for up to 650,000 deaths per year (WHO 2025). Yearly administration of an influenza vaccine for the prevention of influenza is currently recommended. However, the real-world vaccine effectiveness varied from 10% to 60% in the general population across the years of 2004 to 2024, with effectiveness in most years below 50% (CDC 2025) and decreasing to as low as 5% in immunocompromised individuals (Hughes 2021). The goal of this study is to learn whether MK-1406…”In the company’s words, NCT07159763 on ClinicalTrials.gov
Other names
MK-1406

Other drugs for Influenza

All 30 drugs for Influenza

Coming up4

Changes1

Last 90 days

Trials7

TrialPhaseCompletesWhat it tests
Phase 3Recruiting 2 Jul 2027 A Study to Evaluate the Safety and Efficacy of MK-1406/CD388 for Prevention of Influenza (MK-1406-005/CD388.SQ.3.06)
Phase 2Active, not recruiting 31 Jul 2027 A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)
Phase 1Recruiting 31 Dec 2026 A Trial to Evaluate the Effect of CD388/MK1406 on the Immunogenicity of Fluzone® HD Vaccine (CD388.SQ.1.08/MK-1406-007)
Phase 1Recruiting 5 Feb 2027 A Clinical Trial of MK-1406 in Healthy Participants (MK-1406-008)
Phase 2Completed 17 Jul 2023 The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
Phase 1Completed 14 Jul 2023 Study of CD388 Subcutaneous Administration in Healthy Japanese Subjects
Phase 1Completed 27 Oct 2023 Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow CD388

Following is part of Solo: you see every change to CD388 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in